Catalytic efficiencies of directly evolved phosphotriesterase variants with structurally different organophosphorus compounds in vitro
0301 basic medicine
Molecular Structure
Recombinant Fusion Proteins
Computational Biology
Protein Engineering
Clone Cells
High-Throughput Screening Assays
3. Good health
Molecular Docking Simulation
03 medical and health sciences
Organophosphorus Compounds
Phosphoric Triester Hydrolases
Amino Acid Substitution
Bacterial Proteins
Peptide Library
Pseudomonas
Inactivation, Metabolic
Mutation
Biocatalysis
Escherichia coli
Directed Molecular Evolution
Pesticides
Nerve Agents
DOI:
10.1007/s00204-015-1626-2
Publication Date:
2015-11-26T07:07:13Z
AUTHORS (12)
ABSTRACT
The nearly 200,000 fatalities following exposure to organophosphorus (OP) pesticides each year and the omnipresent danger of a terroristic attack with OP nerve agents emphasize the demand for the development of effective OP antidotes. Standard treatments for intoxicated patients with a combination of atropine and an oxime are limited in their efficacy. Thus, research focuses on developing catalytic bioscavengers as an alternative approach using OP-hydrolyzing enzymes such as Brevundimonas diminuta phosphotriesterase (PTE). Recently, a PTE mutant dubbed C23 was engineered, exhibiting reversed stereoselectivity and high catalytic efficiency (k cat/K M) for the hydrolysis of the toxic enantiomers of VX, CVX, and VR. Additionally, C23's ability to prevent systemic toxicity of VX using a low protein dose has been shown in vivo. In this study, the catalytic efficiencies of V-agent hydrolysis by two newly selected PTE variants were determined. Moreover, in order to establish trends in sequence-activity relationships along the pathway of PTE's laboratory evolution, we examined k cat/K M values of several variants with a number of V-type and G-type nerve agents as well as with different OP pesticides. Although none of the new PTE variants exhibited k cat/K M values >107 M-1 min-1 with V-type nerve agents, which is required for effective prophylaxis, they were improved with VR relative to previously evolved variants. The new variants detoxify a broad spectrum of OPs and provide insight into OP hydrolysis and sequence-activity relationships.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (42)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....